Dosage Forms & Drug Delivery Systems – Page 44

Cpv Trending Gap during tech transfer: control strategy build-out for inspections

The first step in addressing a Cpv trending gap is identifying symptoms or signals that indicate potential issues during the tech transfer process. Observational data collected from both the manufacturing…

Control Strategy Weakness during lifecycle management: control strategy build-out for inspections

Identifying symptoms or signals of control strategy weaknesses can be pivotal in early detection. Symptoms may include:Click to read the full article.

Viscosity Drift in ear drop manufacturing: sanitation, water, and EM checks

Identifying early signals of viscosity drift is crucial to prevent broader quality issues. Symptoms can often be detected at various stages:Click to read the full article.

Ivivc Mismatch for modified release platforms: how to document for FDA/EMA/MHRA review

Identifying symptoms related to an IVIVC mismatch is a critical first step in the investigation process. These symptoms may manifest during various development stages through unexpected findings in stability data,…

Ivivc Mismatch during PAI readiness: regulatory-ready investigation and CAPA plan

The first step in identifying an Ivivc mismatch is recognizing the symptoms or signals that indicate a deviation has occurred. Common signals may include:Click to read the full article.

Scale-Up Failure for long-acting injectables: risk assessment and validation impact analysis

Identifying the symptoms of scale-up failure is critical for timely intervention. Common signals may manifest during various manufacturing stages, such as:Click to read the full article.

Phase Separation during method transfer: investigation steps with CAPA evidence

During method transfer, signs of phase separation can manifest immediately during the mixing or when preparing samples for analysis. Recognizing these symptoms is crucial for prompt action. Common indicators include:Click…

Stability Failure after formulation change: control strategy build-out for inspections

Signals indicative of stability failures can manifest at various stages in pharmaceutical manufacturing and quality control. Some common symptoms include:Click to read the full article.

Oos Release Profile for long-acting injectables: how to document for FDA/EMA/MHRA review

A thorough understanding of signals indicating OOS incidents is crucial for timely intervention. Symptoms may arise from various environments—whether on the production floor or in the laboratory. Common signals include:Click…

Sedimentation Oos in ear drop manufacturing: sanitation, water, and EM checks

Recognizing the symptoms of sedimentation OOS is crucial to initiating a timely and effective investigation. The following signals may indicate problems with ear drop formulations:Click to read the full article.

Data Integrity Risk during lifecycle management: how to document for FDA/EMA/MHRA review

Recognizing early signs of data integrity issues is paramount. Symptoms can manifest in various forms, often leading to disruptions in the manufacturing process or questionable quality control results. Key signals…

Control Strategy Weakness for modified release platforms: risk assessment and validation impact analysis

The first step in addressing control strategy weaknesses is the identification of symptoms or signals that suggest a deviation or failure in quality attributes during the production or testing of…